Literature DB >> 6513680

Pharmacokinetic studies with silymarin in human serum and bile.

D Lorenz, P W Lücker, W H Mennicke, N Wetzelsberger.   

Abstract

Six subjects were given orally 560 mg of silymarin (silibinin 240 mg = 8 Legalon 70 dragees). The serum concentration curves and urinary excretion of silibinin, the principal constituent of silymarin, were measured. The maximum serum concentrations were low, ranging from 0.18 to 0.62 microgram/ml. The same was true of renal excretion, which amounted to only 1-2% of the silibinin dose over 24 hours. However, after giving 140 mg of silymarin (silibinin: 60 mg) to patients who had undergone cholecystectomy, bile collected from the T-tube drains was found to contain maximum silibinin concentrations of between 11 and 47 micrograms/ml. Though the dose was four times lower than in the previous experiments, these concentrations were approximately 100 times higher than in the serum. Because complete collection of bile from these patients was impossible and because it was not possible to collect individual samples in the time interval from 12-24 h, the conventional pharmacokinetic parameters required for bioavailability studies could not be calculated. However, computation of the value for AUC0-24 and for "mean time" (MT) provided data which enabled bioavailability comparisons to be made. A study in which the absorption of Legalon 35 and Legalon 70 dragees was compared provides an example for such bioavailability investigations in the bile.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6513680

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  24 in total

1.  FMLP-activated neutrophils evoke histamine release from mast cells.

Authors:  R Fantozzi; S Brunelleschi; A Rubino; S Tarli; E Masini; P F Mannaioni
Journal:  Agents Actions       Date:  1986-04

Review 2.  The use of silymarin in the treatment of liver diseases.

Authors:  R Saller; R Meier; R Brignoli
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  A novel method for the determination of biliary clearance in humans.

Authors:  Giulia Ghibellini; Brendan M Johnson; Richard J Kowalsky; William D Heizer; Kim L R Brouwer
Journal:  AAPS J       Date:  2004-11-23       Impact factor: 4.009

4.  Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.

Authors:  N Barzaghi; F Crema; G Gatti; G Pifferi; E Perucca
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Oct-Dec       Impact factor: 2.441

Review 5.  Phytochemicals for the Management of Melanoma.

Authors:  Harish Chandra Pal; Katherine Marchiony Hunt; Ariana Diamond; Craig A Elmets; Farrukh Afaq
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 6.  Silymarin for HCV infection.

Authors:  Stephen J Polyak; Nicholas H Oberlies; Eve-Isabelle Pécheur; Harel Dahari; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Antivir Ther       Date:  2012-09-25

7.  Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.

Authors:  Chihiro Morishima; Margaret C Shuhart; Chia C Wang; Denise M Paschal; Minjun C Apodaca; Yanze Liu; Derek D Sloan; Tyler N Graf; Nicholas H Oberlies; David Y-W Lee; Keith R Jerome; Stephen J Polyak
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

Review 8.  Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.

Authors:  Stephen J Polyak; Peter Ferenci; Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2013-03       Impact factor: 17.425

9.  Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.

Authors:  Jian Wei Deng; Ji-Hong Shon; Ho-Jung Shin; Soo-Jin Park; Chang-Woo Yeo; Hong-Hao Zhou; Im-Sook Song; Jae-Gook Shin
Journal:  Pharm Res       Date:  2008-01-31       Impact factor: 4.200

10.  Comparative pharmacokinetics of silipide and silymarin in rats.

Authors:  P Morazzoni; A Montalbetti; S Malandrino; G Pifferi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.